Hematologic Malignancy
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
CI-CAN-00006470Explore in graph →
Hematologic7 active trials
- NCIt
- C41233
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006470Explore in graph →
Clinical trials
28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT04517851 |
| Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis |
| active not recruiting |
| Phase 2 |
| 15 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jun 11, 2026 |
| clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials